Sugi Predict

Sugi Predict / Compounds / SCHEMBL16100308

SCHEMBL16100308

SCHEMBL16100308

COc1c(Nc2ccnc(Cl)c2)c(=O)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ SMARCA2 P51531 7/20 0.41
▸ SMARCA4 P51532 6/20 0.41
▸ MAPKAPK2 P49137 3/20 0.38
▸ GRM4 Q14833 1/20 0.37
▸ TGFBR1 P36897 1/20 0.37
▸ PTK2 Q05397 1/20 0.36
▸ ERBB2 P04626 1/20 0.36
▸ PRKACA P17612 1/20 0.36
▸ RPS6KB1 P23443 1/20 0.36
▸ GSK3A P49840 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ IRAK1 P51617 1/20 0.36
▸ RPS6KA3 P51812 1/20 0.36
▸ ROCK1 Q13464 1/20 0.36
▸ CDC42BPA Q5VT25 1/20 0.36
▸ AURKB Q96GD4 1/20 0.36
▸ CSNK1G3 Q9Y6M4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2773250 0.76 MEN1 (0.55) POLBMEN1KMT2AERBB2GSK3A
SCHEMBL2772692 0.74 POLB (0.49) POLBMEN1KMT2APRKACARPS6KB1
SCHEMBL2775637 0.73 RAPGEF4 (0.54) POLBMEN1KMT2A
SCHEMBL4368135 0.73 POLB (0.52) POLBMEN1KMT2AMAPKAPK2ERBB2
SCHEMBL29120691 0.72 IGF1R (0.54) POLBMEN1KMT2AGRM4TGFBR1
SCHEMBL1165239 0.72 MAPT (0.57) POLBMEN1KMT2A
SCHEMBL2990917 0.71 KMT2A (0.81) POLBMEN1KMT2A
SCHEMBL17368524 0.71 NFE2L2 (0.40) TGFBR1
SCHEMBL26113892 0.71 RAPGEF4 (0.50) POLBMEN1KMT2A
SCHEMBL2993822 0.71 POLB (0.51) POLBMEN1KMT2APLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110746424-A MK2 inhibitors and uses thereof 西建卡尔有限责任公司 2020-02-04 — — CN disclosed
US-20190135835-A1 MK2 INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2019-05-09 — — US disclosed
US-20190135835-A1 MK2 INHIBITORS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2019-05-09 — — US disclosed
US-10138256-B2 MK2 inhibitors and uses thereof CELGENE CAR LLC (BM) 2018-11-27 — — US disclosed
EP-2968339-A1 MK2 INHIBITORS AND USES THEREOF Celgene Avilomics Research, Inc. (US) 2016-01-20 — — EP disclosed
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2015-12-31 — — US disclosed
WO-2014149164-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2014-09-25 — — WO disclosed
WO-2014149164-A1 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376208-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, DUSP2, MKNK1 POLB 2489/4885MEN1 2025/4885KMT2A 377/4885
US-10138256-B2 MK2 inhibitors and uses thereof MKNK2, DUSP2, MKNK1 POLB 2489/4885MEN1 2025/4885KMT2A 377/4885
US-20190135835-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, DUSP2, MKNK1 POLB 2489/4885MEN1 2025/4885KMT2A 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.